Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa

被引:47
作者
Anglaret, X
Toure, S
Gourvellec, G
Tchehy, A
Zio, L
Zaho, M
Kassi, MC
Lehou, J
Coulibaly, H
Seyler, C
N'Dri-Yoman, T
Salamon, R
Chêne, G
机构
[1] Univ Victor Segalem, INSERM, Unite 593, F-33076 Bordeaux, France
[2] Programme PAC CI, Abidjan, Cote Ivoire
关键词
HIV; Africa; cohort; survival;
D O I
10.1097/00126334-200403010-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In HIV cohorts in sub-Saharan Africa, documenting vital status of patients lost to follow-up is a major challenge. The effect of specific vital status investigation procedures (VSIPs) on the number of known deaths has never been shown. We assessed the effects of VSIP on survival estimates in a 4-year prospective cohort study in Abidjan, Cote d'Ivoire. As of June 2000, 545 HIV-infected adults had been followed for 1186 person-years, of whom 233 were documented as deceased. Forty-eight percent of deaths were known through scheduled VSIPs, including reading of the newspaper obituaries (2%), telephone calls to relatives (10%), and home visits (36%). Survival probability at 1, 2, and 3 years was estimated to be 0.79, 0.65, and 0.56, respectively. Without VSIP, survival at 1, 2, and 3 years would have been estimated to be 11, 23, and 30% higher, respectively. In this large African capital city, survival estimates closely depended on VSIPs, mainly home visits. We suggest that the percentage of deaths known through VSIPs would be a useful indicator to be added when reporting survival data from urban HIV cohort studies in sub-Saharan Africa.
引用
收藏
页码:320 / 323
页数:4
相关论文
共 7 条
[1]   RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE [J].
ACKAH, AN ;
COULIBALY, D ;
DIGBEU, H ;
DIALLO, K ;
VETTER, KM ;
COULIBALY, IM ;
GREENBERG, AE ;
DECOCK, KM .
LANCET, 1995, 345 (8950) :607-610
[2]   Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire:: a randomised trial [J].
Anglaret, X ;
Chêne, G ;
Attia, A ;
Toure, S ;
Lafont, S ;
Combe, P ;
Manlan, K ;
N'Dri-Yoman, T ;
Salamon, R .
LANCET, 1999, 353 (9163) :1463-1468
[3]   23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial [J].
French, N ;
Nakiyingi, J ;
Carpenter, LM ;
Lugada, E ;
Watera, C ;
Moi, K ;
Moore, M ;
Antvelink, D ;
Mulder, D ;
Janoff, EN ;
Whitworth, J ;
Gilks, CF .
LANCET, 2000, 355 (9221) :2106-2111
[4]  
LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415
[5]   The prognostic value of the World Health Organisation staging system for HIV infection and disease in rural Uganda [J].
Malamba, SS ;
Morgan, D ;
Clayton, T ;
Mayanja, B ;
Okongo, M ;
Whitworth, J .
AIDS, 1999, 13 (18) :2555-2562
[6]  
Senkoro KP, 2000, J ACQ IMMUN DEF SYND, V23, P194
[7]   Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial [J].
Wiktor, SZ ;
Sassan-Morokro, M ;
Grant, AD ;
Abouya, L ;
Karon, JM ;
Maurice, C ;
Djomand, G ;
Ackah, A ;
Domoua, K ;
Kadio, A ;
Yapi, A ;
Combe, P ;
Tossou, O ;
Roels, TH ;
Lackritz, EM ;
Coulibaly, D ;
De Cock, KM ;
Coulibaly, IM ;
Greenberg, AE .
LANCET, 1999, 353 (9163) :1469-1475